NHS introduces Pfizer’s tafamidis for ATTR-CM treatment
The UK’s National Health Service (NHS) has introduced Pfizer‘s tafamidis for transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare heart condition characterised by shortness of breath, fatigue, palpitations, fainting and chest pain. The development …